Triton's primary project portfolio involves development of drug leads in the treatment of cancer, neurological disorders, infectious diseases and applications of immune suppression. The establishment of a fine chemicals repository is a natural extension of this core research focus for new pharmaceuticals. » More
March 25, 2009 - Triton BioPharma commences Commercial Sale of Marine-Derived Fine Chemicals
March 3, 2009 - Triton BioPharma AG launches new multimedia Web Station
February 27, 2009 - Triton BioPharma to be profiled on CNBC Europe
February 19, 2009 - Michael Jarmolowich appointed as Board Member of Triton BioPharma AG
February 13, 2009 - Triton BioPharma establishes Fellowship Program
February 2, 2009 - Triton BioPharma names Mark Hamann as Chief Scientific Officer
January 28, 2009 - Triton BioPharma submits Grant Application to U.S. Department of Defense’s Congressionally Directed Medical Research Program regarding Traumatic Brain Injury Research
January 23, 2009 - Raymond Schinazi joins Triton BioPharma AG as a Board Member
January 15, 2009 - Triton BioPharma Submits Product Development Application to U.S. Department of Defense’s Congressionally Directed Medical Research Program regarding Post-traumatic Stress Disorder Research
December 22, 2008 - Stephan Eschmann is appointed to the Board of Directors of Triton BioPharma AG